title: Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment.
abstract: Peginterferon alpha-2a (PEG IFN α-2a) is frequently used in chronic hepatitis B (CHB)treatment. Numerous adverse events can be noted during this therapy such as flu-like disease, rash, weight loss and depression. However, PEG IFN α-2a related ototoxicity seems to be an uncommon entity. Ototoxicity can be detected objectively by audiometry. In this paper, we present a case of CHB who developed reversible bilateral ototoxicity during PEG IFN α-2a treatment. Due to ototoxicity detected objectively by audiogram, treatment was ceased at sixth month and ototoxicity completely recovered one month after stopping the drug.
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
authors.forename: Hasan Tahsin
authors.initials: HT
authors.lastname: Gozdas
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
authors.forename: Oguz
authors.initials: O
authors.lastname: Karabay
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D001299:Audiometry; D005260:Female; D006309:Hearing / Q000187:drug effects*; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a
keywords: Adverse event; Peginterferon alpha-2a; chronic hepatitis B; ototoxicity
references.citation: Nat Rev Gastroenterol Hepatol. 2011 May;8(5):275-84
references.pmid: 21423260
references.citation: Am J Gastroenterol. 2004 May;99(5):873-7
references.pmid: 15128353
references.citation: World J Gastroenterol. 2007 Oct 28;13(40):5411-2
references.pmid: 17879419
references.citation: Turk J Gastroenterol. 2009 Jun;20(2):156
references.pmid: 19530055
references.citation: Drugs. 2009;69(18):2633-60
references.pmid: 19943712
references.citation: Saudi J Gastroenterol. 2011 Mar-Apr;17(2):114-8
references.pmid: 21372348
references.citation: Auris Nasus Larynx. 2003 Feb;30(1):41-4
references.pmid: 12589849
references.citation: Biomed Res Int. 2013;2013:295327
references.pmid: 23984336